Corbus Pharmaceuticals Holdings, Inc.

CRBP


Canadian symbol: CRBP
US symbol: CRBP

Currency in USD

Valuation Measures

Market Cap (intraday) 5594.42M
Enterprise Value 3535.82M
Trailing P/E N/A
Forward P/E 1-5.32
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)16.50
Price/Book (mrq)26.20
Enterprise Value/Revenue 314.88
Enterprise Value/EBITDA 6-6.74

Trading Information

Stock Price History

Beta (5Y Monthly) 1.42
52-Week Change 316.32%
S&P500 52-Week Change 36.72%
52 Week High 38.78
52 Week Low 33.29
50-Day Moving Average 37.54
200-Day Moving Average 36.19

Share Statistics

Avg Vol (3 month) 31.31M
Avg Vol (10 day) 31.81M
Shares Outstanding 572.49M
Float 63.84M
% Held by Insiders 14.93%
% Held by Institutions 141.18%
Shares Short (Jun. 14, 2020) 411.43M
Short Ratio (Jun. 14, 2020) 47.82
Short % of Float (Jun. 14, 2020) 420.05%
Short % of Shares Outstanding (Jun. 14, 2020) 415.76%
Shares Short (prior month May 14, 2020) 411.79M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020

Profitability

Profit Margin -207.87%
Operating Margin (ttm)-223.40%

Management Effectiveness

Return on Assets (ttm)-60.37%
Return on Equity (ttm)-230.41%

Income Statement

Revenue (ttm)36.02M
Revenue Per Share (ttm)0.55
Quarterly Revenue Growth (yoy)-6.60%
Gross Profit (ttm)-53.46M
EBITDA -79.56M
Net Income Avi to Common (ttm)-74.88M
Diluted EPS (ttm)-1.14
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)46.62M
Total Cash Per Share (mrq)0.64
Total Debt (mrq)9.04M
Total Debt/Equity (mrq)39.82
Current Ratio (mrq)1.58
Book Value Per Share (mrq)0.31

Cash Flow Statement

Operating Cash Flow (ttm)-83.64M
Levered Free Cash Flow (ttm)-63.15M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
CRBP
Corbus Pharmaceuticals
7 months ago
CRBP
Corbus Pharmaceuticals
7 months ago
CRBP
Corbus Pharmaceuticals
7 months ago
CRBP
Corbus Pharmaceuticals
7 months ago
CRBP
Corbus Pharmaceuticals
8 months ago
CRBP
Corbus Pharmaceuticals
9 months ago
CRBP
Corbus Pharmaceuticals
10 months ago
CRBP
Corbus Pharmaceuticals
10 months ago
CRBP
Corbus Pharmaceuticals
10 months ago
CRBP
Corbus Pharmaceuticals
10 months ago
CRBP
Corbus Pharmaceuticals
10 months ago
CRBP
Corbus Pharmaceuticals
11 months ago
CRBP
Corbus Pharmaceuticals
11 months ago
CRBP
Corbus Pharmaceuticals
11 months ago
CRBP
Corbus Pharmaceuticals
12 months ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago
CRBP
Corbus Pharmaceuticals
1 year ago

Currency in USD
Earnings EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts7777
Avg. Estimate-0.38-0.37-1.55-1.54
Low Estimate-0.46-0.48-1.84-2.07
High Estimate-0.32-0.29-1.25-0.62
Year Ago EPS0.03-0.32-1.12-1.55
Revenue EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts7776
Avg. Estimate2.99M1.81M9.42M18.42M
Low EstimateN/AN/A1.8MN/A
High Estimate9.25M4.75M16.01M45.8M
Year Ago Sales3.09M2.59M36.14M9.42M
Sales Growth (year/est)-3.20%-30.10%-73.90%95.50%
Earnings History2019-06-292019-09-292019-12-302020-03-30
EPS Est.-0.36-0.38-0.36-0.4
EPS Actual0.03-0.32-0.41-0.43
Difference0.390.06-0.05-0.03
Surprise %108.30%15.80%-13.90%-7.50%
EPS TrendCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Current Estimate-0.38-0.37-1.55-1.54
7 Days Ago-0.38-0.37-1.55-1.54
30 Days Ago-0.38-0.38-1.57-1.53
60 Days Ago-0.4-0.37-1.6-1.4
90 Days Ago-0.4-0.37-1.6-1.4
EPS RevisionsCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesCRBPIndustrySectorS&P 500
Current Qtr.-1,366.70%N/AN/AN/A
Next Qtr.-15.60%N/AN/AN/A
Current Year-38.40%N/AN/AN/A
Next Year0.60%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
4.93%% of Shares Held by All Insider
41.18%% of Shares Held by Institutions
43.32%% of Float Held by Institutions
141Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Blackrock Inc.5,772,447Mar. 30, 20207.96%30,247,622
Knoll Capital Management, L.P.5,045,870Mar. 30, 20206.96%26,440,358
ETF Managers Group, LLC3,568,345Mar. 30, 20204.92%18,698,127
Vanguard Group, Inc. (The)3,555,102Mar. 30, 20204.90%18,628,734
FMR, LLC1,479,867Mar. 30, 20202.04%7,754,503
Citadel Advisors LLC1,381,970Mar. 30, 20201.91%7,241,522
Shaw D.E. & Co., Inc.1,251,270Mar. 30, 20201.73%6,556,654
Pinnacle Associates, Ltd.1,223,777Mar. 30, 20201.69%6,412,591
State Street Corporation1,156,624Mar. 30, 20201.60%6,060,709
Geode Capital Management, LLC990,587Mar. 30, 20201.37%5,190,675

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
ETF Managers Tr-EFTMG Alternative Harvest ETF3,568,345Mar. 30, 20204.92%18,698,127
Vanguard Total Stock Market Index Fund2,058,225Mar. 30, 20202.84%10,785,099
Fidelity Select Portfolios - Biotechnology1,479,867Mar. 30, 20202.04%7,754,503
iShares Russell 2000 ETF1,455,500Mar. 30, 20202.01%7,626,820
Vanguard Extended Market Index Fund918,159Mar. 30, 20201.27%4,811,153
General American Investors Co712,400Mar. 30, 20200.98%3,732,976
Blackrock Funds-Health Sciences Opportunity Portfolio627,000Mar. 30, 20200.86%3,285,480
iShares NASDAQ Biotechnology ETF615,501Mar. 30, 20200.85%3,225,225
iShares Russell 2000 Growth ETF579,056Mar. 30, 20200.80%3,034,253
AdvisorShares Trust-AdvisorShares Pure Cannabis ETF315,889Mar. 30, 20200.44%1,655,258
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Corbus Pharmaceuticals Holdings, Inc.


Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress

Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress

Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum Phase 2 open-label extension studyACR CRISS score at Week 52 is the primary endpoint in the RESOLVE-1 Phase 3 study of lenabasum in SSc, with topline data on schedul... Read More...
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background CFTR-targeting therapiesTreatment of inflammation to reduce PEx remains a key unmet need in CFStudy is funded in part by a Development Award for up to $25 Million from... Read More...
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis

Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis

Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020Norwood, MA, June 01, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering t... Read More...
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Topline data on schedule for summer 2020Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and JapanThere are no FDA-approved therapies for the overall treatment of SScNorwood, MA, May 27, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or th... Read More...
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress

First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of RESOLVE-1 patients in EUNorwood, MA, May 22, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug developme... Read More...
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates

Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates

Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b study data in cystic fibrosis Phase 1 trial of CRB-4001 remains on track to initiate in third quarter of 2020Recent appointment of Dr. Pete Salzmann to Board of DirectorsImplemented COVID-19 mitigation an... Read More...
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020

Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020

- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET-NORWOOD, MA, May 04, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will... Read More...
Viela Bio Announces Election of Rachelle Jacques to its Board of Directors

Viela Bio Announces Election of Rachelle Jacques to its Board of Directors

GAITHERSBURG, Md., April 30, 2020 -- Viela Bio (VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the election of Rachelle Jacques to its Board of Directors. As a veteran of the biotechnology and pharmaceutical industries, Ms. Jacques has held various leader... Read More...
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology

Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology

These previously presented data demonstrated lenabasum improved efficacy outcomes and underlying disease pathology compared to placebo and had an acceptable safety profile in Phase 2 studySystemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan, and has the highest mortality rate among the system... Read More...
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results

Topline results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibrosisCompleted $46 million public offering in February 2020 Company to host conference call and webcast today, March 12 at 8:30 am ET Norwood, MA, March 12, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (N... Read More...
Corbus Pharmaceuticals Holdings, Inc. to Host Earnings Call

Corbus Pharmaceuticals Holdings, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Corbus Pharmaceuticals Holdings, Inc. (CRBP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 8:30 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/event/present... Read More...
Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director

Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director

Norwood, MA, March 10, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the appointment of Pete Salzmann, M.D., MBA, to its Board of Directors.Dr. Salzmann brings 20... Read More...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020

Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020

- Management to host conference call and webcast on Thursday, March 12 at 8:30 a.m. ET -Norwood, MA, March 05, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that ... Read More...
Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Norwood, MA, Feb. 11, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the closing of its public offering of 7,666,667 shares of its common stock, including 1,000,00... Read More...
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Norwood, MA, Feb. 07, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a pu... Read More...
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock

Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock

Norwood, MA, Feb. 06, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it plans to offer and sell shares of its common stock in an underwritten registered publi... Read More...
Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System

Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System

- Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET Norwood, MA, Dec. 09, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will host ... Read More...
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Company expects to report topline data from study in the summer of 2020Primary endpoint of this study is reduction in pulmonary exacerbationsStudy enrolled participants regardless of CFTR mutation Stable background use of CFTR therapies was permittedMilestone advances Corbus’ vision to pioneer the development of transformative medicines t... Read More...
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile continues with no serious or severe AEs related to lenabasum reported in these studies to dateTopline results from RESOLVE-1 Phase 3 study of lenab... Read More...
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates

Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates

Phase 3 “RESOLVE-1” study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan and has the highest mortality rate among the systemic autoimmune diseasesPhase 2b study of lenabasum for treatment of c... Read More...
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting

Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting

New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presentedSystemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan and has the highest mortality rate among the systemic autoimmune diseasesDermatomyositis is a rare systemic autoimmune disease af... Read More...
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates 

Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates 

Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU and Japan CRB-4001 on course to start Phase 1 study in 2019 as a candidate for NASHProprietary platform generates first group of pre-clinical endocannabinoid mimet... Read More...
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies

Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies

ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis OLE study81% systemic sclerosis subjects remain on lenabasum in the OLE ≥ 21 months; 90% dermatomyositis subjects remain in OLE at ≥ 16 monthsNo serious or severe... Read More...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June

Norwood, MA, May 29, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at... Read More...
Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting

Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting

New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation includes data from some systemic sclerosis subjects who have finished two years dosing with lenabasum Norwood, MA , May 28, 2019 -- Corbus Pharmaceuticals Holdings, Inc.... Read More...
Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates

Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates

Continued progress made in four ongoing clinical studies as lenabasum advances towards 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis Second clinical candidate CRB-4001 expected to commence clinical studies in 2019Platform of proprietary drug candidates positions Corbus to become the leader in the treatment ... Read More...
Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Company anticipates topline results of RESOLVE-1 study in the summer of 2020Systemic sclerosis (SSc) is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and JapanSSc has the highest mortality rate among the systemic autoimmune diseases; there are no FDA-approved treatments for this disease... Read More...
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019

Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019

Norwood, MA, May 01, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced that the Company will host a conference call and live audio webcast on ... Read More...
Coming Soon.

Delayed data (1h)


Share this page